Natus Medical (NASDAQ:BABY) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report released on Saturday.
Other equities analysts have also issued reports about the company. Roth Capital set a $39.00 price objective on Natus Medical and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Benchmark reiterated a “buy” rating and issued a $49.00 price objective (down from $55.00) on shares of Natus Medical in a research note on Tuesday, January 16th. Zacks Investment Research lowered Natus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Finally, William Blair lowered Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Natus Medical has an average rating of “Hold” and an average price target of $44.33.
Shares of Natus Medical (NASDAQ:BABY) opened at $33.35 on Friday. Natus Medical has a 12-month low of $28.00 and a 12-month high of $43.60. The firm has a market capitalization of $1,105.89, a PE ratio of -53.79 and a beta of 0.55. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.32 and a quick ratio of 2.54.
Natus Medical declared that its board has approved a share repurchase program on Thursday, February 22nd that allows the company to repurchase $30.00 million in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.
In other news, Director Ken Ludlum sold 4,000 shares of Natus Medical stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $31.68, for a total value of $126,720.00. Following the transaction, the director now directly owns 93,825 shares in the company, valued at $2,972,376. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.50% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in Natus Medical during the third quarter valued at about $138,000. Elkfork Partners LLC bought a new position in Natus Medical during the fourth quarter valued at about $163,000. Greenwood Capital Associates LLC bought a new position in Natus Medical during the fourth quarter valued at about $219,000. First Capital Advisors Group LLC. bought a new position in Natus Medical during the fourth quarter valued at about $222,000. Finally, Bessemer Group Inc. bought a new position in Natus Medical during the fourth quarter valued at about $255,000. Hedge funds and other institutional investors own 95.81% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://stocknewstimes.com/2018/03/19/natus-medical-baby-rating-increased-to-hold-at-bidaskclub.html.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.